midodrine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
sympathomimetics 1803 42794-76-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • midodrine monohydrochloride
  • midodrin
  • midodrine
  • (+/-)-Midodrine
  • midodrine hydrochloride
  • midodrine HCl
An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.
  • Molecular weight: 254.29
  • Formula: C12H18N2O4
  • CLOGP: -0.35
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 3
  • TPSA: 93.81
  • ALOGS: -1.76
  • ROTB: 6
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
30 mg O

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.98 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 93 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.67 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 27.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.70 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.60 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 4.45 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -0.727 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 2.944 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.665 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 3.581 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 88.330 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 86.980 % High 1
herg hERG pIC50 4.005 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 2.483 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.540 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 91.190 % High 1
kinase-safety-class ACVR2A,ACVR2B,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK7,MET,MTOR,NTRK2,PDK2,PDK4,PIK3CA,PIK3CB,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,ZAP70 43
kinase-selectivity-class AXL,BRAF,EPHB4,GRK2,MAP2K6,PDK4 6
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 1.455 High 1
mh-clint Mouse hepatocyte intrinsic clearance 17.660 High 1
mppb Mouse plasma protein binding (% unbound) 90.500 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 2.393 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 89.290 % High 1
rh-clint Rat hepatocyte intrinsic clearance 7.482 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 95.170 % High 1
rppb Rat plasma protein binding (% unbound) 89.850 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 931.108 uM High 1

Approvals:

DateAgencyCompanyOrphan
Sept. 6, 1996 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypotension 171.01 14.96 243 15335 325154 90287715
Syncope 121.21 14.96 131 15447 132532 90480337
Death 107.60 14.96 240 15338 456311 90156558
Hypervolaemia 107.16 14.96 68 15510 32689 90580180
Supine hypertension 106.82 14.96 17 15561 51 90612818
Dizziness 70.70 14.96 242 15336 589042 90023827
Fall 67.80 14.96 209 15369 481601 90131268
Orthostatic hypotension 64.17 14.96 55 15523 41772 90571097
Blood pressure decreased 58.15 14.96 68 15510 74827 90538042
Presyncope 51.20 14.96 43 15535 31762 90581107
Loss of consciousness 50.19 14.96 88 15490 140150 90472719
Pulmonary arterial hypertension 49.75 14.96 39 15539 26148 90586721
Systemic lupus erythematosus 47.34 14.96 4 15574 361892 90250977
Hepatic enzyme increased 44.52 14.96 5 15573 360731 90252138
Contraindicated product administered 40.63 14.96 4 15574 320135 90292734
Hand deformity 39.52 14.96 3 15575 296359 90316510
Serum amyloid A protein increased 38.53 14.96 11 15567 706 90612163
Hospitalisation 37.81 14.96 74 15504 128026 90484843
Product dose omission issue 36.79 14.96 122 15456 291565 90321304
Arthropathy 36.54 14.96 9 15569 366233 90246636
Joint swelling 35.92 14.96 21 15557 503279 90109590
Pericarditis 35.28 14.96 3 15575 270148 90342721
Right ventricular failure 35.18 14.96 28 15550 19177 90593692
Dialysis 33.30 14.96 22 15556 11307 90601562
Postural orthostatic tachycardia syndrome 32.96 14.96 13 15565 2259 90610610
Fluid retention 32.44 14.96 56 15522 88035 90524834
Rheumatoid arthritis 32.33 14.96 11 15567 362603 90250266
Nephrogenic systemic fibrosis 31.55 14.96 15 15563 4093 90608776
Dyspnoea 31.27 14.96 258 15320 880697 89732172
Human herpesvirus 6 infection reactivation 30.84 14.96 9 15569 625 90612244
Hallucination 29.80 14.96 46 15532 65913 90546956
Wound 29.16 14.96 8 15570 302972 90309897
Endocarditis 28.98 14.96 17 15561 7096 90605773
Cardiac failure congestive 27.89 14.96 56 15522 98638 90514231
Urinary tract infection 27.76 14.96 115 15463 305517 90307352
Sepsis 27.07 14.96 80 15498 179734 90433135
Infusion related reaction 26.21 14.96 20 15558 416760 90196109
Alopecia 26.08 14.96 28 15550 495043 90117826
Therapeutic product effect decreased 25.48 14.96 8 15570 277563 90335306
Myxoedema coma 25.23 14.96 7 15571 405 90612464
Treatment failure 24.16 14.96 11 15567 303917 90308952
End stage renal disease 23.64 14.96 16 15562 8555 90604314
Atrial fibrillation 23.59 14.96 63 15515 133548 90479321
Lower respiratory tract infection 23.41 14.96 7 15571 250652 90362217
Blood cholesterol increased 23.03 14.96 4 15574 208008 90404861
Hereditary neuropathic amyloidosis 23.01 14.96 3 15575 0 90612869
Cardiac amyloidosis 22.62 14.96 8 15570 1028 90611841
Pulmonary hypertension 22.58 14.96 32 15546 42491 90570378
Psoriatic arthropathy 22.02 14.96 6 15572 228329 90384540
Autonomic nervous system imbalance 21.72 14.96 11 15567 3439 90609430
Freezing phenomenon 21.59 14.96 9 15569 1803 90611066
Cardiac failure acute 21.02 14.96 17 15561 11912 90600957
Rehabilitation therapy 20.84 14.96 9 15569 1965 90610904
Stoma site discharge 20.78 14.96 9 15569 1980 90610889
Blood pressure abnormal 20.77 14.96 21 15557 19624 90593245
Dehydration 20.75 14.96 77 15501 194370 90418499
Scleroderma 20.47 14.96 13 15565 6248 90606621
Product administration interrupted 20.33 14.96 17 15561 12475 90600394
Stomatitis 20.23 14.96 11 15567 274687 90338182
Feeling abnormal 20.22 14.96 69 15509 167166 90445703
Discomfort 20.19 14.96 11 15567 274324 90338545
Dyskinesia 20.15 14.96 28 15550 36506 90576363
Retinal artery occlusion 19.63 14.96 9 15569 2262 90610607
Acute respiratory failure 19.48 14.96 30 15548 42888 90569981
Enanthema 19.45 14.96 6 15572 504 90612365
Dialysis hypotension 19.42 14.96 5 15573 217 90612652
Head injury 18.87 14.96 25 15553 31163 90581706
Headache 18.57 14.96 228 15350 862518 89750351
Nausea 18.43 14.96 280 15298 1110036 89502833
Blood pressure orthostatic decreased 18.27 14.96 5 15573 275 90612594
Subdural haematoma 17.97 14.96 18 15560 16627 90596242
Palpitations 17.94 14.96 58 15520 136670 90476199
Hospice care 17.46 14.96 14 15564 9690 90603179
Osteoarthritis 17.32 14.96 6 15572 195724 90417145
Clostridium test positive 17.13 14.96 11 15567 5390 90607479
Fibromyalgia 17.13 14.96 7 15571 206262 90406607
Stoma site irritation 17.11 14.96 5 15573 349 90612520
Hypersensitivity 16.77 14.96 33 15545 454644 90158225
Hypertensive emergency 16.74 14.96 8 15570 2209 90610660
Skin induration 16.55 14.96 9 15569 3253 90609616
Respiratory failure 16.23 14.96 51 15527 118367 90494502
Atrial flutter 16.19 14.96 14 15564 10744 90602125
Maternal exposure during pregnancy 16.17 14.96 23 15555 360040 90252829
Gastrointestinal stoma complication 16.07 14.96 8 15570 2411 90610458
Drug intolerance 16.07 14.96 33 15545 447558 90165311
Wrong patient received product 16.01 14.96 9 15569 3468 90609401
Product use issue 15.91 14.96 20 15558 329899 90282970
Injury 15.90 14.96 7 15571 197342 90415527
Irritable bowel syndrome 15.73 14.96 8 15570 207440 90405429
Inability to afford medication 15.67 14.96 9 15569 3613 90609256
Haemangioma of spleen 15.40 14.96 3 15575 35 90612834
Haemorrhagic stroke 15.28 14.96 11 15567 6485 90606384
Bradycardia 15.27 14.96 40 15538 83807 90529062
Cerebral mass effect 15.12 14.96 6 15572 1060 90611809
Asthenia 15.11 14.96 149 15429 533602 90079267
Hepatic encephalopathy 15.07 14.96 15 15563 13757 90599112

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Orthostatic hypotension 174.27 15.71 112 13128 30458 42577637
Fall 160.69 15.71 272 12968 234248 42373847
Hypotension 133.63 15.71 265 12975 257366 42350729
Death 121.42 15.71 370 12870 470815 42137280
Dizziness 80.67 15.71 213 13027 249041 42359054
Hallucination 80.17 15.71 94 13146 57413 42550682
Syncope 66.04 15.71 114 13126 99292 42508803
Supine hypertension 57.60 15.71 15 13225 370 42607725
Blood pressure decreased 52.65 15.71 77 13163 58255 42549840
Troponin T increased 46.89 15.71 21 13219 2759 42605336
Confusional state 45.96 15.71 135 13105 167462 42440633
Loss of consciousness 41.73 15.71 90 13150 92264 42515831
Blood pressure fluctuation 37.49 15.71 44 13196 26864 42581231
Presyncope 33.52 15.71 38 13202 22349 42585746
Device dislocation 33.39 15.71 24 13216 7807 42600288
Urinary tract infection 33.15 15.71 86 13154 99198 42508897
Multiple system atrophy 31.94 15.71 8 13232 168 42607927
Hypervolaemia 30.87 15.71 37 13203 23088 42585007
Hospitalisation 30.81 15.71 70 13170 74260 42533835
Product dose omission issue 28.60 15.71 109 13131 154256 42453839
N-terminal prohormone brain natriuretic peptide increased 28.32 15.71 16 13224 3437 42604658
Mesenteric artery thrombosis 28.04 15.71 10 13230 724 42607371
Pneumonia 26.32 15.71 222 13018 421927 42186168
Cryptococcal meningoencephalitis 25.80 15.71 7 13233 203 42607892
Hallucination, visual 25.41 15.71 32 13208 20988 42587107
Asthenia 25.11 15.71 161 13079 280632 42327463
Burkholderia test positive 24.56 15.71 10 13230 1040 42607055
Serum amyloid A protein increased 24.01 15.71 7 13233 265 42607830
Orthostatic hypertension 23.98 15.71 8 13232 474 42607621
Cardiac pacemaker evaluation 23.96 15.71 6 13234 126 42607969
Dementia 23.03 15.71 27 13213 16453 42591642
Toxic epidermal necrolysis 22.24 15.71 34 13206 26716 42581379
Freezing phenomenon 21.83 15.71 11 13229 1878 42606217
Cerebrovascular accident 20.85 15.71 72 13168 97088 42511007
Completed suicide 20.09 15.71 3 13237 96462 42511633
Wrong patient received product 20.07 15.71 13 13227 3570 42604525
Akinesia 19.05 15.71 11 13229 2461 42605634
Stoma site discharge 18.25 15.71 9 13231 1467 42606628
Lactobacillus infection 17.78 15.71 6 13234 368 42607727
Toxicity to various agents 17.13 15.71 28 13212 229108 42378987
Troponin I increased 16.61 15.71 11 13229 3135 42604960
Enteral nutrition 16.56 15.71 5 13235 214 42607881
Generalised oedema 16.43 15.71 22 13218 15314 42592781
Intermittent claudication 16.28 15.71 10 13230 2505 42605590
Tricuspid valve disease 16.19 15.71 5 13235 231 42607864
Feeling abnormal 16.10 15.71 53 13187 69733 42538362
Pyrexia 15.76 15.71 66 13174 393976 42214119

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypotension 257.23 13.88 433 23916 523416 110041534
Death 254 13.88 507 23842 698362 109866588
Orthostatic hypotension 184.76 13.88 137 24212 66112 110498838
Fall 152.38 13.88 379 23970 603103 109961847
Syncope 149.78 13.88 203 24146 202333 110362617
Supine hypertension 141.44 13.88 30 24319 421 110564529
Hypervolaemia 121.81 13.88 95 24254 49365 110515585
Dizziness 93.33 13.88 351 23998 697842 109867108
Hallucination 83.13 13.88 107 24242 101325 110463625
Blood pressure decreased 74.05 13.88 108 24241 114983 110449967
Presyncope 71.90 13.88 70 24279 48817 110516133
Hospitalisation 64.60 13.88 114 24235 142379 110422571
Serum amyloid A protein increased 62.56 13.88 18 24331 924 110564026
Loss of consciousness 58.76 13.88 132 24217 196174 110368776
Product dose omission issue 48.97 13.88 169 24180 321613 110243337
Hepatic enzyme increased 47.55 13.88 7 24342 320885 110244065
Arthropathy 45.68 13.88 5 24344 287517 110277433
Pulmonary arterial hypertension 44.85 13.88 45 24304 32523 110532427
Dialysis 44.67 13.88 36 24313 19583 110545367
Contraindicated product administered 43.01 13.88 3 24346 248264 110316686
Cardiac failure congestive 42.36 13.88 99 24250 150901 110414049
Troponin T increased 41.94 13.88 20 24329 4286 110560664
Systemic lupus erythematosus 41.50 13.88 4 24345 254334 110310616
Urinary tract infection 40.12 13.88 160 24189 326122 110238828
Wrong patient received product 39.01 13.88 22 24327 6652 110558298
Fluid retention 38.35 13.88 72 24277 94235 110470715
N-terminal prohormone brain natriuretic peptide increased 38.02 13.88 21 24328 6100 110558850
Joint swelling 37.24 13.88 26 24323 442819 110122131
Pericarditis 36.95 13.88 3 24346 219111 110345839
Rheumatoid arthritis 35.33 13.88 11 24338 299602 110265348
Sepsis 33.63 13.88 152 24197 327194 110237756
Right ventricular failure 32.37 13.88 34 24315 25920 110539030
Psoriatic arthropathy 32.35 13.88 3 24346 196758 110368192
Blood pressure fluctuation 31.51 13.88 58 24291 74766 110490184
Freezing phenomenon 31.29 13.88 14 24335 2595 110562355
Dyskinesia 31.23 13.88 47 24302 51399 110513551
Device dislocation 30.05 13.88 36 24313 31668 110533282
Acute respiratory failure 30.02 13.88 57 24292 75203 110489747
Alopecia 29.89 13.88 22 24327 364731 110200219
Treatment failure 29.57 13.88 12 24337 277222 110287728
Blood pressure orthostatic decreased 29.08 13.88 9 24340 594 110564356
Mesenteric artery thrombosis 28.85 13.88 10 24339 943 110564007
Infusion related reaction 28.72 13.88 25 24324 381137 110183813
Dyspnoea 28.53 13.88 370 23979 1106502 109458448
Drug abuse 28.39 13.88 3 24346 177408 110387542
Cryptococcal meningoencephalitis 28.36 13.88 8 24341 382 110564568
Cerebrovascular accident 28.23 13.88 96 24253 181188 110383762
Blood cholesterol increased 27.43 13.88 4 24345 184781 110380169
Stoma site discharge 27.27 13.88 13 24336 2782 110562168
Endocarditis 27.23 13.88 23 24326 13348 110551602
Arthralgia 27.07 13.88 85 24264 779547 109785403
Inflammation 26.87 13.88 5 24344 193233 110371717
Urinary retention 26.84 13.88 52 24297 69631 110495319
Asthenia 26.79 13.88 250 24099 688749 109876201
Lower respiratory tract infection 26.79 13.88 10 24339 243096 110321854
Stomatitis 26.77 13.88 13 24336 270229 110294721
Cardiac pacemaker evaluation 25.57 13.88 6 24343 136 110564814
Therapeutic product effect decreased 25.37 13.88 11 24338 244305 110320645
Feeling abnormal 24.96 13.88 92 24257 180619 110384331
End stage renal disease 24.78 13.88 27 24322 21446 110543504
Burkholderia test positive 24.65 13.88 8 24341 616 110564334
Generalised oedema 24.52 13.88 32 24317 30672 110534278
Pneumonia 24.23 13.88 297 24052 876417 109688533
Cardiac amyloidosis 24.09 13.88 12 24337 2825 110562125
Rehabilitation therapy 24.03 13.88 11 24338 2150 110562800
Wound 23.65 13.88 11 24338 234426 110330524
Human herpesvirus 6 infection reactivation 23.55 13.88 9 24340 1120 110563830
Completed suicide 23.49 13.88 12 24337 242369 110322581
Postural orthostatic tachycardia syndrome 22.25 13.88 10 24339 1872 110563078
Blood pressure increased 22.20 13.88 114 24235 258259 110306691
Scleroderma 22.02 13.88 15 24334 6326 110558624
Head injury 21.56 13.88 36 24313 42981 110521969
Confusional state 21.27 13.88 176 24173 468504 110096446
Intermittent claudication 21.09 13.88 12 24337 3689 110561261
Clostridium test positive 20.68 13.88 18 24331 10875 110554075
Fibromyalgia 20.63 13.88 6 24343 170903 110394047
Metabolic encephalopathy 20.45 13.88 18 24331 11042 110553908
Hypersensitivity 20.44 13.88 36 24313 403962 110160988
Pleural effusion 20.12 13.88 85 24264 177624 110387326
Inability to afford medication 20.02 13.88 12 24337 4064 110560886
Multiple system atrophy 19.89 13.88 6 24343 363 110564587
Myxoedema coma 19.85 13.88 7 24342 695 110564255
Hallucination, visual 19.65 13.88 33 24316 39572 110525378
Malnutrition 19.60 13.88 27 24322 27252 110537698
Osteoarthritis 19.31 13.88 8 24341 182615 110382335
Nephrogenic systemic fibrosis 19.11 13.88 13 24336 5470 110559480
Chronic hepatic failure 19.11 13.88 8 24341 1263 110563687
Wheezing 18.90 13.88 17 24332 255213 110309737
Blood pressure abnormal 18.90 13.88 24 24325 22400 110542550
Atrial fibrillation 18.81 13.88 100 24249 229542 110335408
Pulmonary hypertension 18.63 13.88 39 24310 55181 110509769
Akinesia 18.54 13.88 11 24338 3656 110561294
Tricuspid valve disease 18.37 13.88 6 24343 472 110564478
Pneumonia aspiration 18.29 13.88 49 24300 81184 110483766
Asthma 18.14 13.88 17 24332 250274 110314676
C-reactive protein increased 18.03 13.88 13 24336 217906 110347044
Transfusion 17.98 13.88 25 24324 25447 110539503
Dizziness postural 17.97 13.88 19 24330 14590 110550360
Seizure 17.90 13.88 96 24253 221089 110343861
Dehydration 17.88 13.88 114 24235 279397 110285553
Musculoskeletal pain 17.83 13.88 9 24340 183014 110381936
Septic shock 17.56 13.88 75 24274 157453 110407497
Hepatic encephalopathy 17.41 13.88 26 24323 28230 110536720
Drug intolerance 17.34 13.88 40 24309 406472 110158478
Peritonitis bacterial 17.23 13.88 16 24333 10517 110554433
Chronic kidney disease 17.16 13.88 46 24303 76245 110488705
Dementia with Lewy bodies 17.00 13.88 7 24342 1059 110563891
Seizure like phenomena 16.90 13.88 9 24340 2432 110562518
Hereditary neuropathic amyloidosis 16.89 13.88 3 24346 15 110564935
Troponin I increased 16.83 13.88 12 24337 5440 110559510
Hospice care 16.74 13.88 17 24332 12456 110552494
On and off phenomenon 16.64 13.88 11 24338 4413 110560537
Somnolence 16.44 13.88 117 24232 297332 110267618
Subarachnoid haemorrhage 16.43 13.88 26 24323 29676 110535274
Sleep disorder 16.24 13.88 12 24337 198632 110366318
Autonomic nervous system imbalance 16.20 13.88 12 24337 5768 110559182
Irritable bowel syndrome 16.11 13.88 8 24341 164207 110400743
Neurotransmitter level altered 16.03 13.88 3 24346 21 110564929
Enteral nutrition 15.89 13.88 5 24344 349 110564601
Speech disorder 15.78 13.88 39 24310 61530 110503420
Intentional product use issue 15.56 13.88 19 24330 247887 110317063
Failure to thrive 15.55 13.88 17 24332 13557 110551393
Arteriovenous fistula site haemorrhage 15.47 13.88 5 24344 380 110564570
Injury 15.43 13.88 10 24339 177255 110387695
Mental status changes 15.24 13.88 44 24305 76078 110488872
Discomfort 15.08 13.88 15 24334 214692 110350258
Dyspepsia 15.02 13.88 12 24337 190953 110373997
Psoriasis 15.02 13.88 6 24343 139987 110424963
Unresponsive to stimuli 14.89 13.88 39 24310 63751 110501199
Vitamin A decreased 14.87 13.88 4 24345 160 110564790
Urticaria 14.73 13.88 30 24319 318827 110246123
Pain 14.68 13.88 137 24212 954818 109610132
Hyperkinesia 14.67 13.88 9 24340 3175 110561775
Swelling 14.60 13.88 35 24314 351006 110213944
Encephalopathy 14.48 13.88 45 24304 81010 110483940
Product administration interrupted 14.45 13.88 15 24334 11277 110553673
Skin induration 14.32 13.88 10 24339 4385 110560565
Hypertensive emergency 14.25 13.88 9 24340 3342 110561608
Plasma cell myeloma 14.20 13.88 38 24311 62898 110502052
Intentional medical device removal by patient 14.11 13.88 5 24344 503 110564447
Device occlusion 13.99 13.88 17 24332 15168 110549782

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C01CA17 CARDIOVASCULAR SYSTEM
CARDIAC THERAPY
CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
Adrenergic and dopaminergic agents
FDA MoA N0000000209 Adrenergic alpha-Agonists
FDA EPC N0000175552 alpha-Adrenergic Agonist
MeSH PA D000316 Adrenergic alpha-Agonists
MeSH PA D002317 Cardiovascular Agents
MeSH PA D013566 Sympathomimetics
MeSH PA D014662 Vasoconstrictor Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018663 Adrenergic Agents
MeSH PA D058646 Adrenergic alpha-1 Receptor Agonists
CHEBI has role CHEBI:35524 sympathomimetic agent
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35569 ฮฑ-adrenergic agonist
CHEBI has role CHEBI:50266 prodrug
CHEBI has role CHEBI:50514 vasoconstrictor agent

Related Drugs by ATC class:

C01CA Adrenergic and dopaminergic agents 25 drugs
amezinium metilsulfatearbutaminecafedrinedimetofrinedobutaminedopaminedopexaminedroxidopaephedrineepinephrineetilefrinefenoldopam show all 25 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Orthostatic hypotension indication 28651003
Acute nephropathy contraindication 58574008
Thyrotoxicosis contraindication 90739004 DOID:7997
Retention of urine contraindication 267064002
Pheochromocytoma contraindication 302835009
Organic Cardiac Disease contraindication
Severe Autonomic Insufficiency contraindication
Supine Hypertension contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.07 acidic
pKa2 13.77 acidic
pKa3 8.39 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Alpha-1A adrenergic receptor GPCR AGONIST WOMBAT-PK CHEMBL
Heat shock protein HSP 90-alpha Cytosolic other IC50 7.70 WOMBAT-PK

External reference:

IDSource
4021003 VUID
N0000179679 NUI
D01307 KEGG_DRUG
43218-56-0 SECONDARY_CAS_RN
4021003 VANDF
4024044 VANDF
C0026078 UMLSCUI
CHEBI:6933 CHEBI
CHEMBL1201212 ChEMBL_ID
CHEMBL1200461 ChEMBL_ID
DB00211 DRUGBANK_ID
D008879 MESH_DESCRIPTOR_UI
4195 PUBCHEM_CID
7240 IUPHAR_LIGAND_ID
3186 INN_ID
6YE7PBM15H UNII
6963 RXNORM
47398 MMSL
5115 MMSL
d04047 MMSL
004074 NDDF
004075 NDDF
108539003 SNOMEDCT_US
108540001 SNOMEDCT_US
372504000 SNOMEDCT_US
6YE7PBM15H INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
MIDODRINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0115-4211 TABLET 2.50 mg ORAL ANDA 25 sections
MIDODRINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0115-4222 TABLET 5 mg ORAL ANDA 25 sections
MIDODRINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0115-4233 TABLET 10 mg ORAL ANDA 25 sections
Midodrine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0245-0211 TABLET 2.50 mg ORAL ANDA 24 sections
Midodrine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0245-0212 TABLET 5 mg ORAL ANDA 24 sections
Midodrine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0245-0213 TABLET 10 mg ORAL ANDA 24 sections
Midodrine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-1901 TABLET 2.50 mg ORAL ANDA 24 sections
Midodrine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-1902 TABLET 5 mg ORAL ANDA 24 sections
Midodrine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-1903 TABLET 10 mg ORAL ANDA 24 sections
Midodrine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-8382 TABLET 2.50 mg ORAL ANDA 21 sections
Midodrine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-8383 TABLET 5 mg ORAL ANDA 21 sections
Midodrine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-8384 TABLET 10 mg ORAL ANDA 21 sections
Midodrine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6817 TABLET 2.50 mg ORAL ANDA 22 sections
Midodrine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6818 TABLET 5 mg ORAL ANDA 22 sections
Midodrine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6819 TABLET 10 mg ORAL ANDA 22 sections
Midodrine HCl HUMAN PRESCRIPTION DRUG LABEL 1 21695-181 TABLET 10 mg ORAL ANDA 21 sections
Midodrine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 23155-969 TABLET 2.50 mg ORAL ANDA 24 sections
Midodrine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 23155-970 TABLET 5 mg ORAL ANDA 24 sections
Midodrine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 23155-971 TABLET 10 mg ORAL ANDA 24 sections
Midodrine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42291-560 TABLET 2.50 mg ORAL ANDA 21 sections
Midodrine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42291-561 TABLET 5 mg ORAL ANDA 21 sections
Midodrine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42291-562 TABLET 10 mg ORAL ANDA 21 sections
MIDODRINE HYDROCHLORIDE Human Prescription Drug Label 1 46708-338 TABLET 2.50 mg ORAL ANDA 20 sections
MIDODRINE HYDROCHLORIDE Human Prescription Drug Label 1 46708-339 TABLET 5 mg ORAL ANDA 20 sections
MIDODRINE HYDROCHLORIDE Human Prescription Drug Label 1 46708-340 TABLET 10 mg ORAL ANDA 20 sections
Midodrine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 48433-075 TABLET 5 mg ORAL ANDA 24 sections
Midodrine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 49884-814 TABLET 2.50 mg ORAL ANDA 20 sections
Midodrine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 49884-849 TABLET 5 mg ORAL ANDA 20 sections
Midodrine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 49884-874 TABLET 10 mg ORAL ANDA 20 sections
Midodrine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50268-561 TABLET 2.50 mg ORAL ANDA 21 sections